Compounds and uses thereof for the modulation of hemoglobin

ABSTRACT

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation and claims benefit under 35 U.S.C. §120 of U.S. application Ser. No. 13/815,776, filed Mar. 15, 2013, nowU.S. Pat. No. 9,458,139. The entire contents of the prior application isincorporated herein by reference in its entirety.

FIELD OF THE INVENTION

This invention provides compounds and pharmaceutical compositionssuitable as allosteric modulators of hemoglobin, methods andintermediates for their preparation, and methods for their use intreating disorders mediated by hemoglobin and disorders that wouldbenefit from tissue and/or cellular oxygenation.

STATE OF THE ART

Sickle cell disease is a disorder of the red blood cells, foundparticularly among those of African and Mediterranean descent. The basisfor sickle cell disease is found in sickle hemoglobin (HbS), whichcontains a point mutation relative to the prevalent peptide sequence ofhemoglobin (Hb).

Hemoglobin (Hb) transports oxygen molecules from the lungs to varioustissues and organs throughout the body. Hemoglobin binds and releasesoxygen through conformational changes. Sickle hemoglobin (HbS) containsa point mutation where glutamic acid is replaced with valine, allowingHbS to become susceptible to polymerization to give the HbS containingred blood cells their characteristic sickle shape. The sickled cells arealso more rigid than normal red blood cells, and their lack offlexibility can lead to blockage of blood vessels. U.S. Pat. No.7,160,910 discloses compounds that are allosteric modulators ofhemoglobin. However, a need exists for additional therapeutics that cantreat disorders that are mediated by Hb or by abnormal Hb such as HbS.

SUMMARY OF THE INVENTION

This invention relates generally to compounds and pharmaceuticalcompositions suitable as allosteric modulators of hemoglobin. In someaspects, this invention relates to methods for treating disordersmediated by hemoglobin and disorders that would benefit from tissueand/or cellular oxygenation.

In certain aspects of the invention, a compound of formula (I) isprovided:

In certain aspects of the invention, a compound of Formula (I) isprovided:

-   -   or a tautomer thereof, or a pharmaceutically acceptable salt of        each thereof, wherein    -   ring A is an optionally substituted 5-10 membered heteroaryl        containing up to 3 ring N, O, and/or S atoms, and oxidized forms        of N and/or S atoms;    -   wherein ring A is α or β substituted relative to the Y        substituent;    -   ring B is an optionally substituted C₆-C₁₀ aryl or 4-10 membered        heterocycle containing up to 5 ring heteroatoms, wherein the        heteroatom is selected from the group consisting of O, N, S, and        oxidized forms of N and S;    -   each Y and Z is independently CR¹⁰R¹¹, O, S, SO, SO₂, or NR¹²;        each R¹⁰ and R¹¹ independently is hydrogen or C₁-C₃ alkyl,        optionally substituted with halo, OH, or alkoxy, or CR¹⁰R¹¹ is        C═O; R¹² is hydrogen or C₁-C₆ alkyl; provided that if one of Y        and Z is O, S, SO, SO₂, then the other is not CO, and provided        that Y and Z are both not heteroatoms or oxidized forms thereof;    -   ring C is C₆-C₁₀ aryl;    -   V¹ and V² independently are C₁-C₆ alkoxy; or V¹ and V² together        with the carbon atom they are attached to form a ring of        formula:

-   -   wherein each V³ and V⁴ are independently O, S, or NH, provided        that when one of V³ and V⁴ is S, the other is NH, and provided        that V³ and V⁴ are both not NH; q is 1 or 2; each V₅ is        independently C₁-C₆ alkyl or CO₂R⁶⁰, where each R⁶⁰        independently is C₁-C₆ alkyl or hydrogen; t is 0, 1, 2, or 4; or        CV¹V² is C═V, wherein V is O, NOR⁸⁰, or NNR⁸¹R⁸²;    -   R⁵ is hydrogen, C₁-C₆ alkyl or a prodrug moiety R, wherein the        C₁-C₆ alkyl is optionally substituted with 1-5 halo;    -   R⁶ is a substituent that is halo, C₁-C₆ alkyl, C₁-C₆ alkoxy,        C₁-C₆ alkylthio, C₁-C₆ S(O)—, C₁-C₆ S(O)2-, wherein the C₁-C₆        alkyl is optionally substituted with 1-5 halo; or    -   R⁶ is 4-10 membered cycloalkyl or heterocycle substituted with        an R′R′N— moiety wherein each R′ is independently C₁-C₆ alkyl or        hydrogen;    -   R⁸⁰ is optionally substituted C₁-C₆ alkyl;    -   R⁸¹ and R⁸² independently are selected from the group consisting        of hydrogen, optionally substituted C₁-C₆ alkyl, COR⁸³, or        CO₂R⁸⁴;    -   R⁸³ is hydrogen or optionally substituted C₁-C₆ alkyl;    -   R⁸⁴ is optionally substituted C₁-C₆ alkyl;    -   k is 0 or 1; and    -   p is 0, 1, 2, or 3.

In further aspects of the invention, a composition is providedcomprising any of the compounds described herein, and at least apharmaceutically acceptable excipient.

In still further aspects of the invention, a method is provided forincreasing oxygen affinity of hemoglobin S in a subject, the methodcomprising administering to a subject in need thereof a therapeuticallyeffective amount of any of the compounds or compositions describedherein.

In further aspects of the invention, a method is provided for treatingoxygen deficiency associated with sickle cell anemia, the methodcomprising administering to a subject in need thereof a therapeuticallyeffective amount of any of the compounds or compositions describedherein.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

It must be noted that as used herein and in the appended claims, thesingular forms “a”, “an”, and “the” include plural referents unless thecontext clearly dictates otherwise. Thus, for example, reference to “asolvent” includes a plurality of such solvents.

As used herein, the term “comprising” or “comprises” is intended to meanthat the compositions and methods include the recited elements, but notexcluding others. “Consisting essentially of” when used to definecompositions and methods, shall mean excluding other elements of anyessential significance to the combination for the stated purpose. Thus,a composition or process consisting essentially of the elements asdefined herein would not exclude other materials or steps that do notmaterially affect the basic and novel characteristic(s) of the claimedinvention. “Consisting of” shall mean excluding more than trace elementsof other ingredients and substantial method steps. Embodiments definedby each of these transition terms are within the scope of thisinvention.

Unless otherwise indicated, all numbers expressing quantities ofingredients, reaction conditions, and so forth used in the specificationand claims are to be understood as being modified in all instances bythe term “about.” Accordingly, unless indicated to the contrary, thenumerical parameters set forth in the following specification andattached claims are approximations. Each numerical parameter should atleast be construed in light of the number of reported significant digitsand by applying ordinary rounding techniques. The term “about” when usedbefore a numerical designation, e.g., temperature, time, amount, andconcentration, including range, indicates approximations which may varyby (+) or (−) 10%, 5% or 1%.

As used herein, C_(m)-C_(n), such as C₁-C₁₂, C₁-C₈, or C₁-C₆ when usedbefore a group refers to that group containing m to n carbon atoms.

The term “alkoxy” refers to —O-alkyl. The term alkylthio refers to—S-alkyl.

The term “alkyl” refers to monovalent saturated aliphatic hydrocarbylgroups having from 1 to 30 carbon atoms (i.e., C₁-C₃₀ alkyl) or 1 to 22carbon atoms (i.e., C₁-C₂₂ alkyl), 1 to 8 carbon atoms (i.e., C₁-C₈alkyl), or 1 to 4 carbon atoms. This term includes, by way of example,linear and branched hydrocarbyl groups such as methyl (CH₃—), ethyl(CH₃CH₂—), n-propyl (CH₃CH₂CH₂—), isopropyl ((CH₃)₂CH—), n-butyl(CH₃CH₂CH₂CH₂—), isobutyl ((CH₃)₂CHCH₂—), sec-butyl ((CH₃)(CH₃CH₂)CH—),t-butyl ((CH₃)₃C—), n-pentyl (CH₃CH₂CH₂CH₂CH₂—), and neopentyl((CH₃)₃CCH₂—).

The term “aryl” refers to a monovalent, aromatic mono- or bicyclic ringhaving 6-10 ring carbon atoms. Examples of aryl include phenyl andnaphthyl. The condensed ring may or may not be aromatic provided thatthe point of attachment is at an aromatic carbon atom. For example, andwithout limitation, the following is an aryl group:

The term “—CO₂H ester” refers to an ester formed between the —CO₂H groupand an alcohol, preferably an aliphatic alcohol. A preferred exampleincluded —CO₂R^(E), wherein R^(E) is alkyl or aryl group optionallysubstituted with an amino group.

The term “chiral moiety” refers to a moiety that is chiral. Such amoiety can possess one or more asymmetric centers. Preferably, thechiral moiety is enantiomerically enriched, and more preferably a singleenantiomer. Non limiting examples of chiral moieties include chiralcarboxylic acids, chiral amines, chiral amino acids, such as thenaturally occurring amino acids, chiral alcohols including chiralsteroids, and the likes.

The term “cycloalkyl” refers to a monovalent, preferably saturated,hydrocarbyl mono-, bi-, or tricyclic ring having 3-12 ring carbon atoms.While cycloalkyl, refers preferably to saturated hydrocarbyl rings, asused herein, it also includes rings containing 1-2 carbon-carbon doublebonds. Nonlimiting examples of cycloalkyl include cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamentyl, and thelike. The condensed rings may or may not be non-aromatic hydrocarbylrings provided that the point of attachment is at a cycloalkyl carbonatom. For example, and without limitation, the following is a cycloalkylgroup:

The term “halo” refers to F, Cl, Br, and/or I.

The term “heteroaryl” refers to a monovalent, aromatic mono-, bi-, ortricyclic ring having 2-16 ring carbon atoms and 1-8 ring heteroatomsselected preferably from N, O, S, and P and oxidized forms of N, S, andP, provided that the ring contains at least 5 ring atoms. Nonlimitingexamples of heteroaryl include furan, imidazole, oxadiazole, oxazole,pyridine, quinoline, and the like. The condensed rings may or may not bea heteroatom containing aromatic ring provided that the point ofattachment is a heteroaryl atom. For example, and without limitation,the following is a heteroaryl group:

The term “heterocyclyl” or heterocycle refers to a non-aromatic, mono-,bi-, or tricyclic ring containing 2-12 ring carbon atoms and 1-8 ringheteroatoms selected preferably from N, O, S, and P and oxidized formsof N, S, and P, provided that the ring contains at least 3 ring atoms.While heterocyclyl preferably refers to saturated ring systems, it alsoincludes ring systems containing 1-3 double bonds, provided that thering is non-aromatic. Nonlimiting examples of heterocyclyl include,azalactones, oxazoline, piperidinyl, piperazinyl, pyrrolidinyl,tetrahydrofuranyl, and tetrahydropyranyl. The condensed rings may or maynot contain a non-aromatic heteroatom containing ring provided that thepoint of attachment is a heterocyclyl group. For example, and withoutlimitation, the following is a heterocyclyl group:

The term “hydrolyzing” refers to breaking an R^(H)—O—CO—, R^(H)—O—CS—,or an R^(H)—O—SO₂— moiety to an R^(H)—OH, preferably by adding wateracross the broken bond. A hydrolyzing is performed using various methodswell known to the skilled artisan, non limiting examples of whichinclude acidic and basic hydrolysis.

The term “oxo” refers to a C═O group, and to a substitution of 2 geminalhydrogen atoms with a C═O group.

The term “optionally substituted” refers to a substituted orunsubstituted group. The group may be substituted with one or moresubstituents, such as e.g., 1, 2, 3, 4 or 5 substituents. Preferably,the substituents are selected from the group consisting of oxo, halo,—CN, NO₂, —N₂+, —CO₂R¹⁰⁰, —OR¹⁰⁰, —SR¹⁰⁰, —SOR¹⁰⁰, —SO₂R¹⁰⁰, —NR¹⁰¹R¹⁰²,—CONR¹⁰¹R¹⁰², —SO₂NR¹⁰¹R¹⁰², C₁-C₆ alkyl, C₁-C₆ alkoxy, —CR¹⁰⁰═C(R¹⁰⁰)₂,—CCR¹⁰⁰, C₃-C₁₀ cycloalkyl, C₃-C₁₀ heterocyclyl, C₆-C₁₂ aryl and C₂-C₁₂heteroaryl, wherein each R¹⁰⁰ independently is hydrogen or C₁-C₈ alkyl;C₃-C₁₂ cycloalkyl; C₃-C₁₀ heterocyclyl; C₆-C₁₂ aryl; or C₂-C₁₂heteroaryl; wherein each alkyl, cycloalkyl, heterocyclyl, aryl, orheteroaryl is optionally substituted with 1-3 halo, 1-3 C₁-C₆ alkyl, 1-3C₁-C₆ haloalkyl or 1-3 C₁-C₆ alkoxy groups. Preferably, the substituentsare selected from the group consisting of chloro, fluoro, —OCH₃, methyl,ethyl, iso-propyl, cyclopropyl, vinyl, ethynyl, —CO₂H, —CO₂CH₃, —OCF₃,—CF₃ and —OCHF₂.

R¹⁰¹ and R¹⁰² independently is hydrogen; C₁-C₈ alkyl, optionallysubstituted with —CO₂H or an ester thereof, C₁-C₆ alkoxy, oxo,—CR¹⁰³═C(R¹⁰³)₂, —CCR, C₃-C₁₀ cycloalkyl, C₃-C₁₀ heterocyclyl, C₆-C₁₂aryl, or C₂-C₁₂ heteroaryl, wherein each R¹⁰³ independently is hydrogenor C₁-C₈ alkyl; C₃-C₁₂ cycloalkyl; C₃-C₁₀ heterocyclyl; C₆-C₁₂ aryl; orC₂-C₁₂ heteroaryl; wherein each cycloalkyl, heterocyclyl, aryl, orheteroaryl is optionally substituted with 1-3 alkyl groups or 1-3 halogroups, or R¹⁰¹ and R¹⁰² together with the nitrogen atom they areattached to form a 5-7 membered heterocycle.

The term “pharmaceutically acceptable” refers to safe and non-toxic forin vivo, preferably, human administration.

The term “pharmaceutically acceptable salt” refers to a salt that ispharmaceutically acceptable.

The term “salt” refers to an ionic compound formed between an acid and abase. When the compound provided herein contains an acidicfunctionality, such salts include, without limitation, alkali metal,alkaline earth metal, and ammonium salts. As used herein, ammonium saltsinclude, salts containing protonated nitrogen bases and alkylatednitrogen bases. Exemplary, and non-limiting cations useful inpharmaceutically acceptable salts include Na, K, Rb, Cs, NH₄, Ca, Ba,imidazolium, and ammonium cations based on naturally occurring aminoacids. When the compounds utilized herein contain basic functionality,such salts include, without limitation, salts of organic acids, such ascarboxylic acids and sulfonic acids, and mineral acids, such as hydrogenhalides, sulfuric acid, phosphoric acid, and the likes. Exemplary andnon-limiting anions useful in pharmaceutically acceptable salts includeoxalate, maleate, acetate, propionate, succinate, tartrate, chloride,sulfate, bisalfate, mono-, di-, and tribasic phosphate, mesylate,tosylate, and the likes.

The terms “treat”, “treating” or “treatment”, as used herein, includealleviating, abating or ameliorating a disease or condition or one ormore symptoms thereof, preventing additional symptoms, ameliorating orpreventing the underlying metabolic causes of symptoms, inhibiting thedisease or condition, e.g., arresting or suppressing the development ofthe disease or condition, relieving the disease or condition, causingregression of the disease or condition, relieving a condition caused bythe disease or condition, or suppressing the symptoms of the disease orcondition, and are intended to include prophylaxis. The terms alsoinclude relieving the disease or conditions, e.g., causing theregression of clinical symptoms. The terms further include achieving atherapeutic benefit and/or a prophylactic benefit. By therapeuticbenefit is meant eradication or amelioration of the underlying disorderbeing treated. Also, a therapeutic benefit is achieved with theeradication or amelioration of one or more of the physiological symptomsassociated with the underlying disorder such that an improvement isobserved in the individual, notwithstanding that the individual is stillbe afflicted with the underlying disorder. For prophylactic benefit, thecompositions are administered to an individual at risk of developing aparticular disease, or to an individual reporting one or more of thephysiological symptoms of a disease, even though a diagnosis of thisdisease has not been made.

The terms “preventing” or “prevention” refer to a reduction in risk ofacquiring a disease or disorder (i.e., causing at least one of theclinical symptoms of the disease not to develop in a subject that may beexposed to or predisposed to the disease but does not yet experience ordisplay symptoms of the disease). The terms further include causing theclinical symptoms not to develop, for example in a subject at risk ofsuffering from such a disease or disorder, thereby substantiallyaverting onset of the disease or disorder.

The term “effective amount” refers to an amount that is effective forthe treatment of a condition or disorder by an intranasal administrationof a compound or composition described herein. In some embodiments, aneffective amount of any of the compositions or dosage forms describedherein is the amount used to treat a disorder mediated by hemoglobin ora disorder that would benefit from tissue and/or cellular oxygenation ofany of the compositions or dosage forms described herein to a subject inneed thereof.

The term “carrier” as used herein, refers to relatively nontoxicchemical compounds or agents that facilitate the incorporation of acompound into cells, e.g., red blood cells, or tissues.

As used herein, a “prodrug” is a compound that, after administration, ismetabolized or otherwise converted to an active or more active form withrespect to at least one property. To produce a prodrug, apharmaceutically active compound can be modified chemically to render itless active or inactive, but the chemical modification is such that anactive form of the compound is generated by metabolic or otherbiological processes. A prodrug may have, relative to the drug, alteredmetabolic stability or transport characteristics, fewer side effects orlower toxicity. For example, see the reference Nogrady, 1985, MedicinalChemistry A Biochemical Approach, Oxford University Press, New York,pages 388-392. Prodrugs can also be prepared using compounds that arenot drugs.

Compounds

In certain aspects of the invention, a compound of Formula (I) isprovided:

-   -   or a tautomer thereof, or a pharmaceutically acceptable salt of        each thereof, wherein    -   ring A is an optionally substituted 5-10 membered heteroaryl        containing up to 3 ring N, O, and/or S atoms, and oxidized forms        of N and/or S atoms;    -   wherein ring A is α or β substituted relative to the Y        substituent;    -   ring B is an optionally substituted C₆-C₁₀ aryl or 4-10 membered        heterocycle containing up to 5 ring heteroatoms, wherein the        heteroatom is selected from the group consisting of O, N, S, and        oxidized forms of N and S;    -   each Y and Z is independently CR¹⁰R¹¹, O, S, SO, SO₂, or NR¹²;        each R¹⁰ and R¹¹ independently is hydrogen or C₁-C₃ alkyl,        optionally substituted with halo, OH, or alkoxy, or CR¹⁰R¹¹ is        C═O; R¹² is hydrogen or C₁-C₆ alkyl; provided that if one of Y        and Z is O, S, SO, SO₂, then the other is not CO, and provided        that Y and Z are both not heteroatoms or oxidized forms thereof;    -   ring C is C₆-C₁₀ aryl;    -   V¹ and V² independently are C₁-C₆ alkoxy; or V¹ and V² together        with the carbon atom they are attached to form a ring of        formula:

-   -   wherein each V³ and V⁴ are independently O, S, or NH, provided        that when one of V³ and V⁴ is S, the other is NH, and provided        that V³ and V⁴ are both not NH; q is 1 or 2; each V₅ is        independently C₁-C₆ alkyl or CO₂R⁶⁰, where each R⁶⁰        independently is C₁-C₆ alkyl or hydrogen; t is 0, 1, 2, or 4; or        CV¹V² is C═V, wherein V is O, NOR⁸⁰, or NNR⁸¹R⁸²;    -   R⁵ is hydrogen, C₁-C₆ alkyl or a prodrug moiety R, wherein the        C₁-C₆ alkyl is optionally substituted with 1-5 halo;    -   R⁶ is a substituent that is halo, C₁-C₆ alkyl, C₁-C₆ alkoxy,        C₁-C₆ alkylthio, C₁-C₆ S(O)—, C₁-C₆ S(O)2-, wherein the C₁-C₆        alkyl is optionally substituted with 1-5 halo; or    -   R⁶ is 4-10 membered cycloalkyl or heterocycle substituted with        an R′R′N— moiety wherein each R′ is independently C₁-C₆ alkyl or        hydrogen;    -   R⁸⁰ is optionally substituted C₁-C₆ alkyl;    -   R⁸¹ and R⁸² independently are selected from the group consisting        of hydrogen, optionally substituted C₁-C₆ alkyl, COR⁸³, or        CO₂R⁸⁴;    -   R⁸³ is hydrogen or optionally substituted C₁-C₆ alkyl;    -   R⁸⁴ is optionally substituted C₁-C₆ alkyl;    -   k is 0 or 1; and    -   p is 0, 1, 2, or 3.

In certain embodiments, t is 0. In certain embodiments, t is 1. Incertain embodiments, t is 2. In certain embodiments, t is 3.

In certain embodiments, Y and Z are both not a heteroatom or aheteroatom containing moiety. In some preferred embodiments, one of Yand Z is a methylene or substituted methylene and the other is aheteroatom or a heteroatom containing moiety. More preferably, Y is analkylene, and Z is a heteroatom or a heteroatom containing moiety,which, yet more preferably is oxygen.

In certain embodiments, V¹ and V² together with the carbon atom they areattached to form a ring of formula:

In certain embodiments, V¹ and V² independently are C₁-C₆ alkoxy; or V¹and V² together with the carbon atom they are attached to form a ring offormula:

wherein each V³ and V⁴ are independently O, S, or NH, provided that whenone or V³ and V⁴ is S the other is NH, and provided that V³ and V⁴ areboth not NH; q is 1 or 2; each V₅ is independently C₁-C₆ alkyl orCO₂R⁶⁰, where each R⁶⁰ independently is C₁-C₆ alkyl or hydrogen; t is 0,1, 2, or 4; or CV¹V² is C═V, wherein V is O, and wherein the remainingvariables are defined herein.

In certain embodiments, the compound is of Formula (I′):

wherein the remaining variables are defined herein.

In certain embodiments, the compound is of Formula IA, IB or IC:

wherein

is an optionally substituted 4-10 membered heterocycle as definedherein, and the remaining variables are defined herein.

In certain embodiments, ring A is substituted with 1-3: halo, OH, C₁-C₆alkyl, and/or C₁-C₆ alkoxy, wherein the C₁-C₆ alkyl is optionallysubstituted with 1-5 halo.

In certain embodiments, ring B is substituted with 1-3: halo, OH, C₁-C₆alkyl, COR¹⁵, and/or COOR¹⁵; and

-   -   R¹⁵ is C₁-C₆ alkyl, C₆-C₁₀ aryl, 5-10 membered heteroaryl or a        4-10 membered heterocycle containing up to 5 ring heteroatoms,        wherein the heteroatom is selected from the group consisting of        O, N, S, and oxidized forms of N and S, wherein the alkyl, aryl,        heteroaryl or heterocyclyl is optionally substituted.

In certain embodiments, Y—Z is —CH₂O—, —CH₂CH₂—, —CONH— or —NHCO—,wherein the right hand side of the substituent is joined with thesubstituted aryl or substituted phenyl ring.

In certain embodiments, the compound is selected from the groupconsisting of

or an N oxide thereof wherein

-   -   Y and Z are as defined herein;    -   x is 0, 1, or 2;    -   R¹⁴ is C₁-C₆ alkyl or C₃-C₈ cycloalkyl, COR¹⁵, or COOR¹⁵;        and R¹⁵ is optionally substituted C₁-C₆ alkyl, optionally        substituted C₆-C₁₀ aryl, optionally substituted 5-10 membered        heteroaryl or optionally substituted 4-10 membered heterocycle        containing up to 5 ring heteroatoms, wherein the heteroatom is        selected from the group consisting of O, N, S, and oxidized        forms of N and S.

In certain embodiments, the compound is selected from the groupconsisting of

or an N oxide thereof wherein

-   -   x is 0, 1, or 2;    -   R¹⁴ is C₁-C₆ alkyl and C₃-C₈ cycloalkyl, COR¹⁵, CNR¹⁵′R¹⁵ or        COOR¹⁵;    -   and R¹⁵ is optionally substituted C₁-C₆ alkyl, optionally        substituted C₆-C₁₀ aryl, optionally substituted 5-10 membered        heteroaryl or optionally substituted 4-10 membered heterocycle        containing up to 5 ring heteroatoms, wherein the heteroatom is        selected from the group consisting of O, N, S, and oxidized        forms of N and S.

In certain aspects of the invention, a compound is provided, wherein thecompound is selected from the group consisting of:

is a double or a single bond.or an N oxide thereof, or a pharmaceutically acceptable salt of eachthereof.Prodrug Moiety

In one aspect, R is hydrogen, a phosphate or a diphosphate containingmoiety, or another promoiety or prodrug moiety. Preferably the prodrugmoiety imparts at least a 2 fold, more preferably a 4 fold, enhancedsolubility and/or bioavailability to the active moiety (where R ishydrogen), and more preferably is hydrolyzed in vivo. The promoietiesare structurally and functionally defined herein.

In one embodiments, R is —COR⁹⁰, CO₂R⁹¹, or CONR⁹²R⁹³ wherein

R⁹⁰ and R⁹¹ independently are C₁-C₆ alkyl, C₃-C₈ cycloalkyl, 4-9membered heterocycle, or a 5-10 membered heteroaryl, each containing atleast 1 basic nitrogen moiety; and

R⁹² and R⁹³ independently are C₁-C₆ alkyl; C₃-C₈ cycloalkyl, 4-9membered heterocycle, or a 5-10 membered heteroaryl, each containing atleast 1 basic nitrogen moiety; or R⁹² and R⁹³ together with the nitrogenatom they are bonded to for a 4-9 member heterocycle substituted with atleast 1 amino, C₁-C₆ alkyl amino, or di C₁-C₆ alkylamino group.

In certain embodiments, R is —C(O)R³¹, C(O)OR³¹, or CON(R¹³)₂,

each R³¹ is independently a C₁-C₆ alkyl; C₃-C₈ cycloalkyl, 4-9 memberedheterocycle, or a 5-10 membered heteroaryl, containing at least 1 basicnitrogen moiety; and

each R¹³ independently are C₁-C₆ alkyl; C₃-C₈ cycloalkyl, 4-9 memberedheterocycle, or a 5-10 membered heteroaryl, containing at least 1 basicnitrogen moiety; or 2 R¹³ moieties together with the nitrogen atom theyare bonded to for a 4-9 member heterocycle substituted with at least 1amino, C₁-C₆ alkyl amino, or di C₁-C₆ alkylamino group.

Preferably, R¹ is isopropyl.

In one aspect, R is C(O)OR³¹, C(S)OR³¹, C(O)SR³¹ or COR³¹, wherein R³¹is as defined herein.

In one embodiment, R³¹ is a group of the formula (CR³²R³³)_(e)NR³⁴R³⁵,wherein

each R³² and R³³ is independently H, a C₁-C₈ alkyl, C₃-C₉ heterocyclyl,C₃-C₈ cycloalkyl, C₆-C₁₀ aryl, C₃-C₉ heteroaryl or R³² and R³³ togetherwith the carbon atom they are bond to form a C₃-C₈ cycloalkyl, C₆-C₁₀aryl, C₃-C₉ heterocyclyl or C₃-C₉ heteroaryl ring system, or 2 adjacentR³² moieties or 2 adjacent R³³ moieties together with the carbon atomthey are bond to form a C₃-C₈ cycloalkyl, C₆-C₁₀ aryl, C₃-C₉heterocyclyl or C₃-C₉ heteroaryl ring system;

each R³⁴ and R³⁵ is a C₁-C₈ alkyl, C₃-C₉ heterocyclyl, C₃-C₈ cycloalkyl,or R³⁴ and R³⁵ together with the nitrogen atom they are bond to form aC₃-C₈ cycloalkyl or C₃-C₉ heterocyclyl ring system;

each heterocyclic and heteroaryl ring system is optionally substitutedwith C₁-C₃ alkyl, —OH, amino and carboxyl groups; and

e is an integer of from 1 to 4.

In some less preferred embodiments R³⁴ and R³⁵ can be hydrogen.

In one embodiment, the subscript e is preferably 2 and each R³² and R³³is preferably independently selected from the group, H, CH₃, and amember in which R³² and R³³ are joined together to form a cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, or1,1-dioxo-hexahydro-IΔ⁶-thiopyran-4-yl or tetrahydropyran-4-yl group.

With regard to the prodrug group, preferred embodiments are compoundswherein NR³⁴R³⁵ is morpholino.

In one embodiment, R is:

wherein

each R³² and R³³ is independently H, C₁-C₈ alkyl, or optionally, if bothpresent on the same substituent, may be joined together to form a C₃-C₈cycloalkyl, C₆-C₁₀ aryl, C₃-C₉ heterocyclyl or C₃-C₉ heteroaryl ringsystem.

Within this embodiment, each R³² and R³³ is independently, H, CH₃, orare joined together to form a cyclopropyl, cyclopbutyl, cyclopentyl,cyclohexyl, 1,1-dioxo-hexahydro-Iλ⁶-thiopyran-4-yl ortetrahydropyran-4-yl group.

In a preferred embodiment, linkage of the prodrug moiety to the rest ofthe active molecule is stable enough so that the serum half life of theprodrug is from about 8 to about 24 hours.

In an embodiment of the invention, the prodrug moiety comprises atertiary amine having a pKa near the physiological pH of 7.5. Any amineshaving a pKa within 1 unit of 7.5 are suitable alternatives amines forthis purpose. The amine may be provided by the amine of a morpholinogroup. This pKa range of 6.5 to 8.5 allows for significantconcentrations of the basic neutral amine to be present in the mildlyalkaline small intestine. The basic, neutral form of the amine prodrugis lipophilic and is absorbed through the wall of the small intestineinto the blood. Following absorption into the bloodstream, the prodrugmoiety is cleaved by esterases which are naturally present in the serumto release an active compound.

Examples of R include, without limitation:

In another embodiment, R is as tabulated below:

R R¹ m R³⁴ R³⁵ NR³⁴R³⁵ C(O)(CH₂)_(m)NR³⁴R³⁵ isopropyl 2 Me MeC(O)(CH₂)_(m)NR³⁴R³⁵ isopropyl 3 Me Me C(O)(CH₂)_(m)NR³⁴R³⁵ isopropyl 4Me Me C(O)(CH₂)_(m)NR³⁴R³⁵ isopropyl 2

C(O)(CH₂)_(m)NR³⁴R³⁵ isopropyl 3

C(O)(CH₂)_(m)NR³⁴R³⁵ isopropyl 4

C(O)O(CH₂)_(m)NR³⁴R³⁵ isopropyl 2 Me Me C(O)O(CH₂)_(m)NR³⁴R³⁵ isopropyl3 Me Me C(O)O(CH₂)_(m)NR³⁴R³⁵ isopropyl 4 Me Me C(O)O(CH₂)_(m)NR³⁴R³⁵isopropyl 2

C(O)O(CH₂)_(m)NR³⁴R³⁵ isopropyl 3

C(O)O(CH₂)_(m)NR³⁴R³⁵ isopropyl 4

P(O)(OH)₂ isopropylan N oxide thereof, or a pharmaceutically acceptable salt of eachthereof.

In another aspect, R is,

wherein

R³⁶ is lower alkyl (e.g. C₁-C₆ alkyl).

In yet another aspect, R is:

wherein X¹, Y¹ and X² are as defined herein.

In one embodiment, X¹ is selected from the group consisting of O, S andNR³⁷ wherein R³⁷ is hydrogen or C₁-C₆ alkyl;

Y¹ is —C(R³⁸)₂ or a sugar moiety, wherein each R³⁸ is independentlyhydrogen or C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₃-C₉ heterocyclyl, C₆-C₁₀aryl, or C₃-C₉ heteroaryl;

X² is selected from the group consisting of halogen, C₁-C₆ alkoxy,diacylglycerol, amino, C₁-C₆ alkylamino, C₁-C₆ dialkylamino, C₁-C₆alkylthio, a PEG moiety, a bile acid moiety, a sugar moiety, an aminoacid moiety, a di- or tri-peptide, a PEG carboxylic acid, and —U—Vwherein

U is O or S; and

V is selected from the group consisting of C₁-C₆ alkyl, C₃-C₈cycloalkyl, C₃-C₉ heterocyclyl, C₆-C₁₀ aryl, C₃-C₉ heteroaryl, C(W²)X³,PO(X³)₂, and SO₂X³;

wherein W² is O or NR³⁹

wherein R³⁹ is hydrogen or C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₃-C₉hetrocyclyl, C₆-C₁₀ aryl, or C₃-C₉ heteroaryl; and

each X³ is independently amino, hydroxyl, mercapto, C₁-C₆ alkyl,heteroalkyl, cycloalkyl, hetrocyclyl, aryl, or heteroaryl, C₁-C₆ alkoxy,C₁-C₆ alkylamino, C₁-C₆ dialkylamino, C₁-C₆ alkylthio, a bile acid basedalkoxy group, a sugar moiety, a PEG moiety, and —O—CH₂—CH(OR⁴⁰)CH₂X⁴R⁴⁰,

wherein:

X⁴ is selected from the group consisting of O, S, S═O, and SO₂; and

each R⁴⁰ is independently C₁₀-C₂₂ alkyl, C₃-C₈ cycloalkyl, C₃-C₉heterocyclyl, C₆-C₁₀ aryl, or C₃-C₉ heteroaryl, C₁-C₈ alkylene, or C₁-C₈heteroalkylene.

Each heterocyclic and heteroaryl ring system is optionally substitutedwith C₁-C₃ alkyl, —OH, amino and carboxyl groups.

In one embodiment, the present invention utilizes the following Y¹groups: CH₂, CHMe, CH(isopropyl), CH(tertiarybutyl), C(Me)₂, C(Et)₂,C(isopropyl)₂, and C(propyl)₂.

In another embodiment, the present invention utilizes the following X²groups:

—OMe, —OEt, —O-isopropyl, O-isobutyl, O-tertiarybutyl, —O—COMe,—O—C(═O)(isopropyl), —O—C(═O)(isobutyl), —O—C(═O)(tertiarybutyl),—O—C(═O)—NMe₂, —O—C(═O)—NHMe, —O—C(═O)—NH₂, —O—C(═O)—N(H)—CH(R⁴¹)—CO₂Etwherein R⁴¹ is a side chain C₁-C₆ alkyl, or C₃-C₉ heterocyclyl groupselected from the side chain groups present in essential amino acids;—O—P(═O)(OMe)₂, —O—P(═O)(O-isopropyl)₂, and —O—P(═O)(O-isobutyl)₂. Eachheterocyclic is optionally substituted with one or more, preferably,1-3, C₁-C₃ alkyl, —OH, amino and/or carboxyl groups.

In another embodiment, in one embodiment, R is:

wherein

X³ is independently C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₃-C₉ heterocyclyl,C₆-C₁₀ aryl, or C₃-C₉ heteroaryl; and

R⁴² is independently hydrogen or C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₃-C₉heterocyclyl, C₆-C₁₀ aryl, or C₃-C₉ heteroaryl.

Each heterocyclic is optionally substituted with one or more,preferably, 1-3, C₁-C₃ alkyl, —OH, amino and/or carboxyl groups.

In one embodiment, R is:

wherein

each X³ is independently amino, hydroxyl, mercapto, C₁-C₆ alkyl, C₃-C₈cycloalkyl, C₃-C₉ heterocyclyl, C₆-C₁₀ aryl, or C₃-C₉ heteroaryl, C₁-C₆alkoxy, C₁-C₆ alkylamino, C₁-C₆ dialkylamino, C₁-C₆ alkylthio, a bileacid based alkoxy group, a sugar moiety, a PEG moiety, and—O—CH₂—CH(OR⁴⁰)CH₂X⁴R⁴⁰,

wherein:

X⁴ is selected from the group consisting of O, S, S═O, and SO₂; and

each R⁴⁰ is independently C₁₀-C₂₂ alkyl, C₃-C₈ cycloalkyl, C₃-C₉heterocyclyl, C₆-C₁₀ aryl, C₃-C₉ heteroaryl, C₁-C₈ alkylene, or C₁-C₈heteroalkylene; and

R⁴² is independently hydrogen or C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₃-C₉heterocyclyl, C₆-C₁₀ aryl, or C₃-C₉ heteroaryl.

In some embodiments, R⁴² is independently hydrogen or C₁-C₆ alkyl, C₃-C₈cycloalkyl, C₃-C₉ heterocyclyl, C₆-C₁₀ aryl, or C₃-C₉ heteroaryl; andeach X³ independently is C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₃-C₉heterocyclyl, C₆-C₁₀ aryl, or C₃-C₉ heteroaryl, C₁-C₆ alkoxy, C₁-C₆alkylamino, C₁-C₆ dialkylamino, or C₁-C₆ alkylthio.

In some embodiments, R is represented by the following structures:

wherein, in the above examples, R⁴³ is C₁₀-C₂₂ alkyl or alkylene, R⁴⁴ isH or C₁-C₆ alkyl and R⁴⁵ represents side chain alkyl groups present innaturally occurring alpha amino acids;

wherein R⁴⁶ is (CH₂)_(n), f=2-4, and CO—R⁴⁷—NH₂ represents an aminoacylgroup; or

wherein R⁴⁶ is (CH₂)_(n), n=2-4, R⁴⁷ is (CH₂)_(n), n=1-3 and R⁴⁹ is O orNMe.

In one embodiment, R is:

In one aspect, R is —C(R²⁰⁰R²⁰¹)O(R²⁰²R²⁰³)P(O)OR²⁰⁴NR²⁰⁵R²⁰⁶, whereineach R²⁰⁰, R²⁰¹, R²⁰², R²⁰³, R²⁰⁴ R²⁰⁵ and R²⁰⁶ is independently H, aC₁-C₈ alkyl, C₃-C₉ heterocyclyl, C₃-C₈ cycloalkyl, C₆-C₁₀ aryl, C₃-C₉heteroaryl, wherein each alkyl, heterocyclyl, cycloalkyl, aryl, andheteroaryl is optionally substituted.

In some embodiments, R is —CH(R²⁰¹)OCH²P(O)OR²⁰⁴NHR²⁰⁶, wherein R²⁰¹ isC₁-C₈ alkyl, R²⁰⁴ is phenyl, optionally substituted. In one embodiment,R²⁰⁶ is —CHR²⁰⁷C(O)OR²⁰⁸ wherein R²⁰⁷ is selected from the groupconsisting of the naturally occurring amino acid side chains and CO₂Hesters thereof and R²⁰⁸ is C₁-C₈ alkyl. In one embodiment, R²⁰⁶ is C₁-C₆alkyl, optionally substituted with 1-3, CO₂H, SH, NH₂, C₆-C₁₀ aryl, andC₂-C₁₀ heteroaryl.

In some embodiments, R is:

In one embodiment, R is:

wherein Y¹ is —C(R³⁸)₂, wherein each R³⁸ is independently hydrogen orC₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₃-C₉ heterocyclyl, C₆-C₁₀ aryl, or C₃-C₉heteroaryl.

Various polyethylene glycol (PEG) moieties and synthetic methods relatedto them that can be used or adapted to make compounds of the inventionare described in U.S. Pat. Nos. 6,608,076; 6,395,266; 6,194,580;6,153,655; 6,127,355; 6,111,107; 5,965,566; 5,880,131; 5,840,900;6,011,042 and 5,681,567.

In one embodiment, R is

wherein

R⁵⁰ is —OH or hydrogen;

R⁵¹ is —OH, or hydrogen;

W is —CH(CH₃)W¹;

wherein W¹ is a substituted C₁-C₈ alkyl group containing a moiety whichis optionally negatively charged at physiological pH,

said moiety is selected from the group consisting of CO₂H, SO₃H, SO₂H,—P(O)(OR⁵²)(OH), —OP(O)(OR⁵²)(OH), and OSO₃H,

wherein R⁵² is C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₃-C₉ heterocyclyl, C₆-C₁₀aryl, or C₃-C₉ heteroaryl.

Each heterocyclic and heteroaryl ring system is optionally substitutedwith one or more, preferably 1-3, C₁-C₃ alkyl, —OH, amino and/orcarboxyl groups.

In one embodiment, R is:

wherein R⁵³ is H or C₁-C₆ alkyl.

In another aspect, R is SO₃H.

In another aspect, R comprises a cleavable linker, wherein the term“cleavable linker” refers to a linker which has a short half life invivo. The breakdown of the linker Z in a compound releases or generatesthe active compound. In one embodiment, the cleavable linker has a halflife of less than ten hours. In one embodiment, the cleavable linker hasa half life of less than an hour. In one embodiment, the half life ofthe cleavable linker is between one and fifteen minutes. In oneembodiment, the cleavable linker has at least one connection with thestructure: C*—C(═X*)X*—C* wherein C* is a substituted or unsubstitutedmethylene group, and X* is S or O. In one embodiment, the cleavablelinker has at least one C*—C(═O)O—C* connection. In one embodiment, thecleavable linker has at least one C*—C(═O)S—C* connection. In oneembodiment, the cleavable linker has at least one—C(═O)N*—C*—SO₂—N*-connection, wherein N* is —NH— or C₁-C₆ alkylamino.In one embodiment, the cleavable linker is hydrolyzed by an esteraseenzyme.

In one embodiment, the linker is a self-immolating linker, such as thatdisclosed in U.S. patent publication 2002/0147138, to Firestone; PCTAppl. No. US05/08161 and PCT Pub. No. 2004/087075. In anotherembodiment, the linker is a substrate for enzymes. See generallyRooseboom et al., 2004, Pharmacol. Rev. 56:53-102.

Pharmaceutical Compositions

In further aspects of the invention, a composition is providedcomprising any of the compounds described herein, and at least apharmaceutically acceptable excipient.

In another aspect, this invention provides a composition comprising anyof the compounds described herein, and a pharmaceutically acceptableexcipient.

Such compositions can be formulated for different routes ofadministration. Although compositions suitable for oral delivery willprobably be used most frequently, other routes that may be used includetransdermal, intravenous, intraarterial, pulmonary, rectal, nasal,vaginal, lingual, intramuscular, intraperitoneal, intracutaneous,intracranial, and subcutaneous routes. Suitable dosage forms foradministering any of the compounds described herein include tablets,capsules, pills, powders, aerosols, suppositories, parenterals, and oralliquids, including suspensions, solutions and emulsions. Sustainedrelease dosage forms may also be used, for example, in a transdermalpatch form. All dosage forms may be prepared using methods that arestandard in the art (see e.g., Remington's Pharmaceutical Sciences,16^(th) ed., A. Oslo editor, Easton Pa. 1980).

Pharmaceutically acceptable excipients are non-toxic, aidadministration, and do not adversely affect the therapeutic benefit ofthe compound of this invention. Such excipients may be any solid,liquid, semi-solid or, in the case of an aerosol composition, gaseousexcipient that is generally available to one of skill in the art.Pharmaceutical compositions in accordance with the invention areprepared by conventional means using methods known in the art.

The compositions disclosed herein may be used in conjunction with any ofthe vehicles and excipients commonly employed in pharmaceuticalpreparations, e.g., talc, gum arabic, lactose, starch, magnesiumstearate, cocoa butter, aqueous or non-aqueous solvents, oils, paraffinderivatives, glycols, etc. Coloring and flavoring agents may also beadded to preparations, particularly to those for oral administration.Solutions can be prepared using water or physiologically compatibleorganic solvents such as ethanol, 1,2-propylene glycol, polyglycols,dimethylsulfoxide, fatty alcohols, triglycerides, partial esters ofglycerin and the like.

Solid pharmaceutical excipients include starch, cellulose, hydroxypropylcellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour,chalk, silica gel, magnesium stearate, sodium stearate, glycerolmonostearate, sodium chloride, dried skim milk and the like. Liquid andsemisolid excipients may be selected from glycerol, propylene glycol,water, ethanol and various oils, including those of petroleum, animal,vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineraloil, sesame oil, etc. In certain embodiments, the compositions providedherein comprises one or more of α-tocopherol, gum arabic, and/orhydroxypropyl cellulose.

In one embodiment, this invention provides sustained releaseformulations such as drug depots or patches comprising an effectiveamount of a compound provided herein. In another embodiment, the patchfurther comprises gum Arabic or hydroxypropyl cellulose separately or incombination, in the presence of alpha-tocopherol. Preferably, thehydroxypropyl cellulose has an average MW of from 10,000 to 100,000. Ina more preferred embodiment, the hydroxypropyl cellulose has an averageMW of from 5,000 to 50,000.

Compounds and pharmaceutical compositions of this invention maybe usedalone or in combination with other compounds. When administered withanother agent, the co-administration can be in any manner in which thepharmacological effects of both are manifest in the patient at the sametime. Thus, co-administration does not require that a singlepharmaceutical composition, the same dosage form, or even the same routeof administration be used for administration of both the compound ofthis invention and the other agent or that the two agents beadministered at precisely the same time. However, co-administration willbe accomplished most conveniently by the same dosage form and the sameroute of administration, at substantially the same time. Obviously, suchadministration most advantageously proceeds by delivering both activeingredients simultaneously in a novel pharmaceutical composition inaccordance with the present invention.

Methods of Treatment

In aspects of the invention, a method is provided for increasing tissueand/or cellular oxygenation, the method comprising administering to asubject in need thereof a therapeutically effective amount of any of thecompounds or compositions described herein.

In aspects of the invention, a method is provided for increasing oxygenaffinity of hemoglobin S in a subject, the method comprisingadministering to a subject in need thereof a therapeutically effectiveamount of any of the compounds or compositions described herein.

In aspects of the invention, a method is provided for treating acondition associated with oxygen deficiency, the method comprisingadministering to a subject in need thereof a therapeutically effectiveamount of any of the compounds or compositions described herein.

In further aspects of the invention, a method is provided for treatingoxygen deficiency associated with sickle cell anemia, the methodcomprising administering to a subject in need thereof a therapeuticallyeffective amount of any of the compounds or compositions describedherein.

In further aspects of the invention, a method is provided for treatingsickle cell disease, the method comprising administering to a subject inneed thereof a therapeutically effective amount of a compound of any ofthe compounds or compositions described herein. In still further aspectsof the invention, a method is provided for treating cancer, a pulmonarydisorder, stroke, high altitude sickness, an ulcer, a pressure sore,Alzheimer's disease, acute respiratory disease syndrome, and a wound,the method comprising administering to a subject in need thereof atherapeutically effective amount of a compound of any of the compoundsor compositions described herein.

Synthetic Methods

Certain methods for making the compounds described herein are alsoprovided. The reactions are preferably carried out in a suitable inertsolvent that will be apparent to the skilled artisan upon reading thisdisclosure, for a sufficient period of time to ensure substantialcompletion of the reaction as observed by thin layer chromatography,¹H-NMR, etc. If needed to speed up the reaction, the reaction mixturecan be heated, as is well known to the skilled artisan. The final andthe intermediate compounds are purified, if necessary, by various artknown methods such as crystallization, precipitation, columnchromatography, and the likes, as will be apparent to the skilledartisan upon reading this disclosure.

An illustrative and non-limiting method for synthesizing a compound offormula (I), is schematically shown below.

In the following Schemes,

refer to rings A, B and C as described herein.

A⁵ and B⁵ are independently NR⁷⁰, O, S, S(O)x, NBoC, CH₂, CHR⁷⁰, C(R₇₀)₂provided that when only one of A⁵ or B⁵ is present, then A⁵ or B⁵ is notCH₂, CHR⁷⁰, C(R⁷⁰)₂, and when both A⁵ and B⁵ are present in a ring, bothare not CH₂, CHR⁷⁰, C(R⁷⁰)₂;

wherein R⁷⁰ is C₁-C₆ alkyl or defined as R⁷⁰ as defined herein;

X, and X⁵ represent a leaving group and are independently selected fromCl, F, Br, and I.

R⁷¹ is C₁-C₆ alkyl;

R⁷² is C₁-C₆ alkyl;

n is 0, 1, or 2;

General Synthetic Schemes

General method A for preparing aryloxy ether analogs (4a) fromsubstituted methylene alcohol (1) and hydroxyl aryl aldehyde derivatives(3a). A hydroxyl (hetero)arylaldehyde derivatives (3a) (0.1-2 mmol)mixture with substituted methylene alcohol (1) (0.8 to 1.2 eq) and PPh₃(1-1.5 eq) in anhydrous THF (1-10 mL) was stirred under nitrogen untilcomplete dissolution. The solution was cooled to 0° C. on ice bath andDIAD or DEAD (1.1 eq) in THF or toluene was added dropwise over a 1-20min period. The ice cooling bath was allowed to expire over 90 min andthe mixture was stirred at RT for 2-48 hours. The mixture was stirredfor 10 min, then filtered through a pad of silica. The silica was washedwith ethyl acetate 2-20 mL. The combined filtrates were evaporated andthe residue was dried on highvac. The residue was purified bypreparative HPLC or flash silica gel chromatography.

General method B for preparing aryloxyether analogs (4a) fromsubstituted methylene halide (2) and hydroxyl aryl aldehyde derivatives(3a). A mixture of hydroxyl (hetero)arylaldehyde derivatives (3a) (0.1-2mmol, 1-4 eq.), substituted methylene chloride or bromide (2) (1 eq),and K₂CO₃ (2-5 eq.) (catalytic amount of NaI or Bu₄NI may also be added)in DMF or acetonitrile (1 to 10 mL) was stirred at RT or heating up to120° C. for 0.5-8 h under nitrogen atmosphere. In workup A, water wasadded to the reaction mixture, the precipitated product was collected,washed with water, and then subjected to preparative HPLC or flashsilica gel chromatography purification. In workup B (for products thatdid not precipitate), diluted HCl or aqueous NH₄Cl was added at 0° C. toadjusted the pH to ^(˜)7, the reaction mixture was partitioned betweenethyl acetate or dichloromethane and aqueous sodium chloride and theorganic layer separated, dried, and solvent removed under vacuum toafford crude product which was purified by automated silica gel columnchromatography using appropriate solvents mixture (e.g., ethylacetate/hexanes).

General method C for preparing substituted methylene chloride (2a). To asolution of substituted methylene alcohol (1) (0.1 to 2 mmol) in DCM(1-10 mL) was added SOCl₂ dropwise (2 eq to 5 eq) at 0° C. or RT. Thereaction mixture was stirred at RT for 10 min to 6 h, or until reactionis judged complete (LC/MS). The reaction mixture is concentrated todryness over a rotavap. The crude chloride residue was suspended intoluene, sonicated and concentrated to dryness. The process was repeatedthree times and dried under vacuum to give the substituted methylenechloride (2), usually as an off-white solid, which was used for nextstep without further purification. Alternatively, a solution of aqueous1N Na₂CO₃ is then added to produce a solution of pH^(˜)8. the mixturewas extracted with DCM (3×10-50 mL), dried over sodium sulfate, andconcentrated to the crude substituted methylene chloride (2a), which isthen purified by column chromatography on silica gel (0-100% ethylacetate-hexanes).

General method D for preparing substituted methylene bromide (2b). To asolution of substituted methylene alcohol (1) (0.1 to 2 mmol) in DCM(1-10 mL) was added Ph₃P Br₂ dropwise (2 eq to 5 eq) at 0° C. or RT. Thereaction mixture was stirred at RT for 10 min to 2 h, or until reactionis judged complete (LC/MS). The reaction mixture is concentrated todryness over a rotavap. The residue purified by column chromatography onsilica gel (0-100% ethyl acetate-hexanes) to afford the pure bromide 2b.

General method E for preparing heterocyclic methylene derivatives 9, 10,12 and 13. Condensation of heterocyclic ketone analog 5 withchlorformate or dialkyl carbonate gives (hetero)cyclic beta-ketone ester6 (Step 1). The ketone ester 6 is converted to the triflate intermediate7 by treating with a triflating agent (e.g, triflic anhydride) in thepresence of an organic base such as Hunig's base (Step 2). Suzukicoupling of the triflate 7 with a boronic acid or ester affordsheterocyclohexene carboxylate 8 (Step 3). Subsequent reduction of theester group by LAH or DIBAL gives the corresponding alcohol 9-OH (Step4). Further reaction of the alcohol 9-OH with thionyl chloride, Ph₃PBr₂(or CBr₄-Ph₃P or PBr₃), or alkyl/aryl sufonyl chloride produces thecorresponding 10-X chloride, bromide or sulfonate (Step 5).

Alternatively, the double bond of heterocyclohexene carboxylate 8 isreduced to give the cis-heterocyclohexane 11-cis carboxylate underpalladium catalyzed hydrogenation conditions (Step 6). Reduction of theester group of 11-cis by LAH or DIBAL yields cis-alcohol 12-OH-cis (Step8). Conversion of the alcohol 12-OH-cis to its chloride, bromide orsulfonate (such as mesylate, tosylate) 13-X-cis can be achieved byreacting with thionyl chloride, or Ph₃PBr₂, or sufonyl chloride (such asmesyl chloride or tosyl chloride) (Step 9). The cis-cyclohexanecarboxylate 11-cis can also be isomerized to the thermodynamically morestable trans-isomer 11-trans by the treatment with an alcoholic alkoxide(e.g., ethoxide) solution. Analogously, transformation of 11-trans esterto 12-trans alcohol and 13-X-trans halide is accomplished by applyingconditions of Step 8 and Step 9 similar to these for the correspondingcis-isomers.

Coupling of the (hetero)cyclic methylene derivatives 9, 10, 12 and 13with hydroxyl (hetero)arylaldehyde derivatives (3a/3b) by general methodA or B affords the corresponding aryloxy/heteroarylether analogs (4c and4d).

General method F for preparing heterocyclic methylene derivatives 18,19, 20 and 21. The ketone ester 14 is converted to the triflateintermediate 15 by treating with a triflating agent (e.g, triflicanhydride) in the presence of an organic base such as Hunig's base (Step1). Suzuki coupling of the triflate 15 with a boronic acid or esteraffords heterocyclo carboxylate 16 (Step 2). Subsequent reduction of theester group by LAH or DIBAL gives the corresponding alcohol 18 (Step 3).Further reaction of the alcohol 18 with thionyl chloride, Ph₃PBr₂ (orCBr₄-Ph₃P or PBr₃), or alkyl/aryl sufonyl chloride produces thecorresponding 19 chloride, bromide or sulfonate (Step 4).

Alternatively, the double bond of 16 is reduced to give the saturatedheterolic analog 17 under palladium catalyzed hydrogenation conditions(Step 5). Reduction of the ester group of 17 by LAH or DIBAL yieldsalcohol 20 (Step 7). Conversion of the alcohol 20 to its chloride,bromide or sulfonate (such as mesylate, tosylate) 21 can be achieved byreacting with thionyl chloride, or Ph₃PBr₂, or sufonyl chloride (such asmesyl chloride or tosyl chloride) (Step 8).

Coupling of the (hetero)cyclic methylene derivatives 18, 19, 20 and 21with hydroxyl (hetero)arylaldehyde derivatives (3a/3b) by general methodA or B affords the corresponding aryloxy/heteroaryloxyether analogs (4eand 4f).

Chiral pyrrolidine methylene derivatives 25 and 26 can be preparedaccording to reaction sequence depicted herein. The pyrrolidine ester 24is produced via a 1,3-dipolar cycloaddition of alkene 22 withazomethine-ylide generated in situ from formaldehyde and amino acid 23alkene (Step 1). Subsequent reduction of the ester to alcohol 24 andfurther conversion 25 are accomplished by analogous methods describedherein. If a chiral auxiliary group such as chiral oxazolidinonederivative 22a is used, optically active pyrrolidine derivatives 25 and26 can also be obtained. Coupling of 25 and 26 with hydroxyl(hetero)arylaldehyde derivatives (3a/3b) by general method A or Baffords the corresponding aryloxy/heteroaryloxyether analogs (4).

Separate from the general synthesis of tetrahydrothiophenes (i.e., 20and 21, A⁵=S) described herein, also described is a different syntheticapproach to this class of analogs.

Other heterocyclic analogs (compound 5) with C—N linkage are synthesizedby applying Buchwald/Hartwig amination conditions. Many of the cyclicamines (1) are available commercially (e.g., 1a, 1b, 1c, 1d, and 1e).

Protected amides of formula —CONHR⁹⁵ and —CONHOR⁹⁵ can be convertede.g., hydrolyzed to the corresponding amides according to methods knownto the skilled artisan.

Prodrug Synthesis

Syntheses of the ester prodrugs start with the free carboxylic acidbearing the tertiary amine. The free acid is activated for esterformation in an aprotic solvent and then reacted with a free alcoholgroup in the presence of an inert base, such as triethyl amine, toprovide the ester prodrug. Activating conditions for the carboxylic acidinclude forming the acid chloride using oxalyl chloride or thionylchloride in an aprotic solvent, optionally with a catalytic amount ofdimethyl formamide, followed by evaporation. Examples of aproticsolvents, include, but are not limited to methylene chloride,tetrahydrofuran, and the like. Alternatively, activations can beperformed in situ by using reagents such as BOP (benzotriazol-l-yloxytris(dimethylamino)phosphonium hexafluorolphosphate, and the like(see Nagy et al., 1993, Proc. Natl. Acad. Sci. USA 90:6373-6376)followed by reaction with the free alcohol. Isolation of the esterproducts can be affected by extraction with an organic solvent, such asethyl acetate or methylene chloride, against a mildly acidic aqueoussolution; followed by base treatment of the acidic aqueous phase so asto render it basic; followed by extraction with an organic solvent, forexample ethyl acetate or methylene chroride; evaporation of the organicsolvent layer; and recrystalization from a solvent, such as ethanol.Optionally, the solvent can be acidified with an acid, such as HCl oracetic acid to provide a pharmaceutically acceptable salt thereof.Alternatively the crude reaction can be passed over an ion exchangecolumn bearing sulfonic acid groups in the protonated form, washed withdeionized water, and eluted with aqueous ammonia; followed byevaporation.

Suitable free acids bearing the tertiary amine are commerciallyavailable, such as 2-(N-morpholino)-propionic acid,N,N-dimethyl-beta-alanine, and the like. Non-commercial acids can besynthesized in straightforward manner via standard literatureprocedures.

Carbonate and carbamate prodrugs can be prepared in an analogous way.For example, amino alcohols and diamines can be activated usingactivating agents such as phosgene or carbonyl diimidazole, to providean activated carbonates, which in turn can react with the alcohol and/orthe phenolic hydroxy group on the compounds utilized herein to providecarbonate and carbamate prodrugs.

Various protecting groups and synthetic methods related to them that canbe used or adapted to make compounds of the invention can be adaptedfrom the references Testa et al., Hydrolysis in Drug and ProdrugMetabolism, June 2003, Wiley-VCH, Zurich, 419-534 and Beaumont et al.,Curr. Drug Metab. 2003, 4:461-85.

Provided herein is a method of synthesizing an acyloxymethyl version ofa prodrug by adapting a method from the reference Sobolev et al., 2002,J. Org. Chem. 67:401-410.

R⁵¹ is C₁-C₆ alkyl.

Provided herein is a method for synthesizing a phosphonooxymethylversion of a prodrug by adapting a method from Mantyla et al., 2004, J.Med. Chem. 47:188-195.

Provided herein is a method of synthesizing an alkyloxymethyl version ofa prodrug

R⁵² is C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₃-C₉ heterocyclyl, C₆-C₁₀ aryl,or C₃-C₉ heteroaryl.

EXAMPLES

The following examples are given for the purpose of illustrating variousembodiments of the invention and are not meant to limit the presentinvention in any fashion. The present examples, along with the methodsdescribed herein are presently representative of preferred embodiments,are exemplary, and are not intended as limitations on the scope of theinvention. Changes therein and other uses which are encompassed withinthe spirit of the invention as defined by the scope of the claims willoccur to those skilled in the art.

In the examples below as well as throughout the application, thefollowing abbreviations have the following meanings. If not defined, theterms have their generally accepted meanings.

-   -   ° C.=degrees Celsius    -   RT=Room temperature    -   min=minute(s)    -   h=hour(s)    -   μL=Microliter    -   mL=Milliliter    -   mmol=Millimole    -   eq=Equivalent    -   mg=Milligram    -   ppm=Parts per million    -   atm=Atmospheric pressure    -   MS=Mass spectrometry    -   LC-MS=Liquid chromatography-mass spectrometry    -   HPLC=High performance liquid chromatography    -   NMR=Nuclear magnetic resonance    -   Sat. Saturated    -   MeOH=Methanol    -   EtOH=Ethanol    -   EtOAc=Ethyl acetate    -   Et₃N=Triethylamine    -   ACN=Acetonitrile    -   AC₂O=Acetic anhydride    -   Na(OAc)₃BH=Sodium triacetoxy borohydride    -   PBr₃=phosphorus tribromide    -   Ph₃P=Triphenylphosphine    -   Ph₃PBr₂=Triphenylphosphine dibromide    -   CBr₄ Tetrabromomethane    -   DMF=N, N-Dimethylformamide    -   DCM=Dichloromethane    -   LAH/LiAlH₄=Lithium aluminum hydride    -   THF=Tetrahydrofuran    -   DIBAL=Diisobutylaluminium hydride    -   DIAD=Diisopropyl azodicarboxylate    -   DEAD=Diethyl azodicarboxylate    -   DIPEA=N,N-Diisopropylethylamine    -   Tf₂O=Trifluoromethanesulfonic (triflic) anhydride    -   Pd(dppf)Cl₂=[1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II),        complex

Preparation of2-hydroxy-6-((5-(1-isopropyl-1H-pyrazol-5-yl)-3,6-dihydro-2H-pyran-4-yl)methoxy)benzaldehyde

Step 1: To a solution of ethyl 3-oxotetrahydro-2H-pyran-4-carboxylate(1.0 g, 5.81 mmol) in DCM (30 mL) was added DIPEA (1.22 mL, 6.97 mmol)and Tf₂O (1.08 mL, 6.39 mmol) at −78° C., then it was warmed up to roomtemperature and stirred at room temperature for 2 h, the solution wasdiluted with DCM, washed with Sat. NaHCO₃, brine, dried and concentratedto give ethyl5-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydro-2H-pyran-4-carboxylate ascrude product (2 g).

Step 2: To a solution of ethyl5-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydro-2H-pyran-4-carboxylate(crude from step 1) and1-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(1.37 g, 5.82 mmol) in dioxane (20 ml) was added Pd(dppf)Cl₂ (430 mg,0.58 mmol) and Na₂CO₃ (1.85 g, 17.46 mmol) in water (6 mL), the mixturewas degased with N2 for 5 min, and was heated at 100° C. for 15 h, aftercooling to room temperature the mixture was diluted with EtOAc andwashed with Sat. NaHCO₃ and brine, organic layer was combined, dried andconcentrated to give crude product, which was purified by columnchromatography (Hexanes/EtOAc=3:1) to give ethyl5-(1-isopropyl-1H-pyrazol-5-yl)-3,6-dihydro-2H-pyran-4-carboxylate (850mg).

Step 3: To a solution of ethyl5-(1-isopropyl-1H-pyrazol-5-yl)-3,6-dihydro-2H-pyran-4-carboxylate (600mg, 2.27 mmol) in THF (10 mL) was added LiAlH₄ (1M in THF, 2.72 mL, 2.72mmol) at −20° C., the reaction was stirred at −20° C. for 30 min, andwas quenched with Sat. NH₄Cl, the aqueous layer was extracted withEtOAc, the combined organics were washed with brine, dried andconcentrated to give crude oil, which was purified by column(Hexanes/EtOAc=100:0 to 20:80) to give(5-(1-isopropyl-1H-pyrazol-5-yl)-3,6-dihydro-2H-pyran-4-yl)methanol (500mg).

Step 4: To a solution of(5-(1-isopropyl-1H-pyrazol-5-yl)-3,6-dihydro-2H-pyran-4-yl)methanol (300mg, 1.35 mmol) in DCM (5 mL) was added dibromotriphenylphosphorane (630mg, 1.35 mmol) at room temperature, after stirring for 30 min, it wasdiluted with DCM, organic layer was washed with Sat. NaHCO₃, brine,dried and concentrated to give crude product, which was purified bycolumn (Hexanes/EtOAc=4:1) to give5-(4-(bromomethyl)-5,6-dihydro-2H-pyran-3-yl)-1-isopropyl-1H-pyrazole(360 mg).

Step 5: To a solution of5-(4-(bromomethyl)-5,6-dihydro-2H-pyran-3-yl)-1-isopropyl-1H-pyrazole(110 mg, 0.38 mmol) and 2,6-dihydroxybenzaldehyde (100 mg, 0.76 mmol) inDMF (6 mL) was added K₂CO₃ (110 mg, 0.76 mmol). After stirred at roomtemperature for 1 h, it was diluted with water and EtOAc, organic layerwas separated, and the aqueous layer was extracted with EtOAc. Organiclayer was combined, washed with brine, dried and concentrated to givecrude product, which was purified by column (Hexanes/EtOAc=1:1) to give2-hydroxy-6-((5-(1-isopropyl-1H-pyrazol-5-yl)-3,6-dihydro-2H-pyran-4-yl)methoxy)benzaldehyde(90 mg). 1H NMR (400 MHz, CDCl₃) δ (ppm) 11.89 (s, 1H), 10.33 (s, 1H),7.53 (d, J=1.6 Hz, 1H), 7.33 (t, J=8.8 Hz, 1H), 6.51 (d, J=8.8 Hz, 1H),6.16 (d, J=8.0 Hz, 1H), 6.08 (d, J=2.0 Hz, 1H), 4.40 (dd, J=12.8, 6.4Hz, 1H), 4.35 (s, 2H), 4.18 (s, 2H), 3.97 (t, J=5.2 Hz, 2H), 2.44 (s,2H), 1.40 (d, J=6.4 Hz, 6H); MS (ESI) m/z 343.3 [M+H]⁺.

Preparation of2-[[1-acetyl-5-(2-propan-2-ylpyrazol-3-yl)-3,6-dihydro-2H-pyridin-4-yl]methoxy]-6-hydroxybenzaldehyde

Step 1: To a solution of(5-(1-isopropyl-1H-pyrazol-5-yl)-1,2,3,6-tetrahydropyridin-4-yl)methanolhydrochloride (110 mg, 0.41 mmol) in DCM (2 mL) at 0° C. was added Et₃N(0.12 mL, 0.82 mmol) and a solution of AC₂O (0.04 mL, 0.41 mmol) in DCM(0.4 mL), after stirred for 15 min, it was diluted with Sat. NH₄Cl andEtOAc, organic layer was separated and the aqueous layer was furtherextracted with EtOAc, organic layers were combined, washed with Sat.NaHCO₃, brine, dried over Na₂SO₄, and was concentrated to give1-(4-(hydroxymethyl)-5-(1-isopropyl-1H-pyrazol-5-yl)-3,6-dihydropyridin-1(2H)-yl)ethan-1-oneas crude product.

Step 2: To a solution of1-(4-(hydroxymethyl)-3-phenyl-5,6-dihydropyridin-1(2H)-yl)ethanone (88mg, 0.41 mmol) in DCM (2 mL) was added SOCl₂ (0.58 mL, 8.25 mmol). Afterstirred at RT for 15 min, the mixture was concentrated and dried underhigh vacuum to give1-(4-(chloromethyl)-5-(1-isopropyl-1H-pyrazol-5-yl)-3,6-dihydropyridin-1(2H)-yl)ethan-1-oneas crude product (80 mg).

Step 3: To a suspension of K₂CO₃ (80 mg, 0.56 mmol) and2,6-dihydroxybenzaldehyde (80 mg, 0.56 mmol) in DMF (2 ml) was added asolution of1-(4-(chloromethyl)-5-(1-isopropyl-1H-pyrazol-5-yl)-3,6-dihydropyridin-1(2H)-yl)ethan-1-one(80 mg, 0.28 mmol) in DMF (2 mL), the mixture was heated at 50° C. for 3h, cooled to room temperature, and was diluted with EtOAc, organic layerwas separated and aqueous layer was extracted with EtOAc. EtOAc layerswere combined, washed with Sat. NaHCO₃, brine, dried over Na₂SO₄, andwas concentrated to give crude oil, which was purified by preparativeHPLC (eluted with ACN/H₂O) to give2-((1-acetyl-5-(1-isopropyl-1H-pyrazol-5-yl)-1,2,3,6-tetrahydropyridin-4-yl)methoxy)-6-hydroxybenzaldehyde(9 mg). 1H NMR (400 MHz, CDCl₃, NMR shows rotamer exist, only one set ofsignal was reported) δ (ppm) 11.87 (s, 1H), 10.34 (s, 1H), 7.54 (d,J=1.6 Hz, 1H), 7.34 (t, J=8.0 Hz, 1H), 6.53 (d, J=8.4 Hz, 1H), 6.15 (d,J=8.4 Hz, 1H), 6.11 (d, J=1.6 Hz, 1H), 4.36 (s, 2H), 4.34 (m, 1H), 4.21(s, 2H), 3.71 (t, J=6.0 Hz, 2H), 2.51 (m, 2H), 2.19 (s, 3H), 1.42 (d,J=6.8 Hz, 6H); MS (ESI) m/z 384.3 [M+H]⁺

Preparation of2-hydroxy-6-[[1-methyl-5-(2-propan-2-ylpyrazol-3-yl)-3,6-dihydro-2H-pyridin-4-yl]methoxy]benzaldehyde

Step 1: To a solid of tert-butyl4-(hydroxymethyl)-5-(1-isopropyl-1H-pyrazol-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate(150 mg, 0.47 mmol) in round bottom flask was added 4N HCl in dioxane (3mL) at room temperature, and was stirred for 1 h, then the mixture wasconcentrated and dried under high vacuum to give(5-(1-isopropyl-1H-pyrazol-5-yl)-1,2,3,6-tetrahydropyridin-4-yl)methanolas HCl salt (120 mg).

Step 2: To a solution of(5-(1-isopropyl-1H-pyrazol-5-yl)-1,2,3,6-tetrahydropyridin-4-yl)methanolhydrochloride in ACN (3 mL) was added Et₃N followed by formalin. Afterstirred at room temperature for 10 min, it was added Na(OAc)₃BH andafter another 30 min, the mixture was concentrated and pass through ashort silica gel column, the column was washed with 10% MeOH in CHCl₃,and then the filtrated was collected and concentrated to give crudeproduct, which was further diluted with EtOAc, filtered to get rid oftriethylamine HCl salt, the filtrate was concentrated again to give(5-(1-isopropyl-1H-pyrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridin-4-yl)methanol(100 mg).

Step 3: To a solution of(5-(1-isopropyl-1H-pyrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridin-4-yl)methanol(100 mg, 0.42 mmol) in DCM (2.5 mL) was added SOCl₂ (0.76 mL, 10.5 mmol)at room temperature and then was stirred at room temperature for 30 min,the mixture was concentrated and diluted with toluene and concentrated,dried under high vacuum to give4-(chloromethyl)-5-(1-isopropyl-1H-pyrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridineas crude product.

Step 4: To a suspension of K₂CO₃ (230 mg, 1.68 mmol) and2,6-dihydroxybenzaldehyde (120 mg, 0.84 mmol) in DMF (2 ml) was added asolution of4-(chloromethyl)-5-(1-isopropyl-1H-pyrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridine(110 mg, 0.42 mmol) in DMF (3 mL), the mixture was heated at 50° C. for4 h, cooled to room temperature, and was diluted with EtOAc, organiclayer was separated and aqueous layer was extracted with EtOAc. EtOAclayer was combined, washed with Sat. NaHCO₃, brine, dried over Na₂SO₄,and was concentrated to give crude oil, which was purified by column(Hexane/EtOAc=65:35 followed by DCM/MeOH=95:5) to give2-hydroxy-6-((5-(1-isopropyl-1H-pyrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridin-4-yl)methoxy)benzaldehyde(44 mg). 1H NMR (400 MHz, CDCl₃) δ (ppm) 11.89 (s, 1H), 10.34 (s, 1H),7.52 (d, J=1.6 Hz, 1H), 7.31 (dd, J=8.4, 7.2 Hz, 1H), 6.51 (d, J=8.4 Hz,1H), 6.16 (d, J=7.2 Hz, 1H), 6.07 (d, J=1.6 Hz, 1H), 4.36 (m, 1H), 4.34(s, 2H), 3.07 (s, 2H), 2.71 (s, 2H), 2.52 (s, 2H), 2.43 (s, 3H), 1.41(d, J=6.4 Hz, 6H); MS (ESI) m/z 356.3 [M+H]⁺.

The following exemplary A-ring and B-ring intermediates may also beincorporated into the compounds of the invention.

Preparation of:

Step 1: To a solution of 1-tert-butyl 4-ethyl3-oxopiperidine-1,4-dicarboxylate (2.0 g, 7.37 mmol) in DCM (45 mL) wasadded DIPEA (1.54 ml, 8.84 mmol) and Tf₂O (1.36 mL, 8.11 mmol) at −78°C., then the temperature was warmed up to room temperature and thesolution was stirred at RT for 1.5 h, the mixture was diluted with DCM(100 mL), organic layer was washed with Sat. NaHCO₃, brine, dried andconcentrated to give 1-(tert-butyl) 4-ethyl5-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1,4(2H)-dicarboxylate,which was used for next step without purification.

Step 2: To a solution of 1-tert-butyl 4-ethyl3-(((trifluoromethyl)sulfonyl)oxy)-5,6-dihydropyridine-1,4(2H)-dicarboxylate(1.49 g, 3.7 mmol) and (1-isopropyl-1H-pyrazol-5-yl)boronic acid (0.57g, 3.7 mmol) in dioxane (10 mL) was added Pd(dppf)Cl₂ (0.27 g, 0.37mmol) and a solution of sodium carbonate (1.18 g, 11.10) in water (3ml), the mixture was degased with N₂ for 5 min, and was heated at 100°C. for 15 h, after cooling to room temperature the mixture was dilutedwith EtOAc and washed with Sat. NaHCO₃ and brine, organic layer wascombined, dried and concentrated to give crude product, which waspurified by column chromatography (Hexanes/EtOAc=3:1) to give desiredproduct 830 mg (62%).

Step 3: To a solution of 1-(tert-butyl) 4-ethyl5-(1-isopropyl-1H-pyrazol-5-yl)-3,6-dihydropyridine-1,4(2H)-dicarboxylate(450 mg, 1.24 mmol) in THF (6 mL) was added LiAlH₄ (1M in THF, 1.49 mL,1.49 mmol) at −20° C., the reaction was stirred at −20° C. for 30 min,and was quenched with Sat. NH₄Cl, the aqueous layer was extracted withEtOAc, the combined organics were washed with brine, dried andconcentrated to give crude oil, which was purified by column(Hexanes/EtOAc=100:0 to 40:60) to give tert-butyl4-(hydroxymethyl)-5-(1-isopropyl-1H-pyrazol-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate(370 mg, 91%).

Step 4: To a solution of give tert-butyl4-(hydroxymethyl)-5-(1-isopropyl-1H-pyrazol-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate(25 mg, 0.08 mmol) in DCM (1 mL) was added triphenylphosphine bromineadduct (40 mg, 0.09 mmol) at room temperature, after stirring for 30min, it was diluted with DCM, washed with Sat. NaHCO3, brine, dried andconcentrated to give crude product, which was purified by column to givetert-butyl4-(bromomethyl)-5-(1-isopropyl-1H-pyrazol-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate(18 mg).

Preparation of2-hydroxy-6-[[cis-3-(2-propan-2-ylpyrazol-3-yl)oxan-4-yl]methoxy]benzaldehyde

Step 1: To a solution of ethyl5-(1-isopropyl-1H-pyrazol-5-yl)-3,6-dihydro-2H-pyran-4-carboxylate (100mg, 0.38 mmol) in EtOH (2 mL) was added Pd/C (50 mg), then it wascharged with H₂ (1 atm) and stirred at room temperature for 3 days, Massspec shows about 50% conversion. The mixture was then added a solutionof NH₄CO₂H (200 mg) in water (2 ml) and additional Pd/C, and the mixturewas further heated at 75° C. for 1.5 h, after cooled to roomtemperature, the reaction was diluted with EtOH, pd/C was filtered off,and the filtrate was concentrated to give crude oil, which was dilutedwith CHCl3, organic layer was washed with Sat. NaHCO₃, dried andconcentrated to give crude product, which was purified by column(Hexanes/EtOAc=65:35) to give (±) ethyl(3S,4R)-3-(1-isopropyl-1H-pyrazol-5-yl)tetrahydro-2H-pyran-4-carboxylate(70 mg).

Step 2: To a solution of (±) (3S,4R)-ethyl3-(1-isopropyl-1H-pyrazol-5-yl)tetrahydro-2H-pyran-4-carboxylate (70 mg,0.26 mmol) in THF (1.5 mL) at −15° C. was added 1M LiAH₄ solution in THF(0.34 mL, 0.34 mmol) slowly. After stirred for 30 min, it was quenchedwith Sat. NH₄Cl; the mixture was extracted with EtOAc. Organic layerswere combined, dried and concentrated to give (±)(3S,4R)-3-(1-isopropyl-1H-pyrazol-5-yl)tetrahydro-2H-pyran-4-yl)methanolas crude product (60 mg).

Step 3: To a solution of (±)((3S,4R)-3-(1-isopropyl-1H-pyrazol-5-yl)tetrahydro-2H-pyran-4-yl)methanol(50 mg, 0.22 mmol) and 2,6-dihydroxybenzaldehyde (60 mg, 0.44 mmol) inTHF (1 mL) was added PPh₃ (120 mg, 0.44 mmol) and DIAD (0.09 mL, 0.44mmol) at 0° C. After stirred for 30 min, the solution was concentratedand the residue was purified by column (Hexanes/EtOAc=60:40) to giveimpure product, which was further purified by prep HPLC (eluted withACN/H₂O) to give (±)2-hydroxy-6-(((3S,4R)-3-(1-isopropyl-1H-pyrazol-5-yl)tetrahydro-2H-pyran-4-yl)methoxy)benzaldehyde(6 mg). 1H NMR (400 MHz, CDCl₃) δ (ppm) 11.90 (s, 1H), 10.36 (s, 1H),7.79 (s, 1H), 7.50 (d, J=2.0 Hz, 1H), 7.32 (t, J=8.8 Hz, 1H), 6.52 (d,J=8.4 Hz, 1H), 6.43 (d, J=1.6 Hz, 1H), 6.16 (d, J=8.0 Hz, 1H), 4.46 (m,1H), 4.13 (dt, J=11.2, 4.0 Hz, 1H), 3.95 (dd, J=11.2, 3.2 Hz, 1H), 3.81(dd, J=11.6, 3.2 Hz, 1H), 3.73 (dd, J=9.2, 5.6 Hz, 1H), 3.65 (dt,J=11.6, 3.2 Hz, 1H), 3.57 (t, J=8.8 Hz, 1H), 3.28 (d, J=4.0 Hz, 1H),2.56 (m, 1H), 1.87 (m, 1H), 1.58 (m, 1H), 1.31 (d, J=6.8 Hz, 3H), 1.29(d, J=7.6 Hz, 3H); MS (ESI) m/z 334.3 [M+H]⁺.

Step 5: To a solution of tert-butyl4-(bromomethyl)-5-(1-isopropyl-1H-pyrazol-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate(18 mg, 0.05 mmol) and

10 mg, 0.06 mmol) in DMF (1 mL) is added K₂CO₃ (14 mg, 0.1 mmol). Afterstirring at room temperature for 1 h, it is diluted with water andEtOAc, organic layer is separated, and the aqueous layer is extractedwith EtOAc, organic layer is combined, washed with brine, dried andconcetrated to give crude product, which is purified by column(Hexanes/EtOAc=2:1.

From the foregoing it will be appreciated that, although specificembodiments of the invention have been described herein for purposes ofillustration, various modifications may be made without deviating fromthe spirit and scope of the invention.

Throughout the description of this invention, reference is made tovarious patent applications and publications, each of which are hereinincorporated by reference in their entirety.

The invention claimed is:
 1. A compound of Formula (I):

or a tautomer thereof, or a pharmaceutically acceptable salt of eachthereof, wherein ring A is a heteroaryl selected from the groupconsisting of furanyl, imidazolyl, oxadiazolyl, oxazolyl, pyrazolyl, andpyridinyl, wherein the heteroaryl is optionally substituted with 1-3substituents independently selected from the group consisting of halo,OH, C₁-C₆ alkyl, and C₁-C₆ alkoxy, wherein the C₁-C₆ alkyl is optionallysubstituted with 1-5 halo; wherein ring A is α substituted relative tothe Y substituent; ring B is a heterocycle selected from the groupconsisting of oxazolinyl, piperidinyl, piperazinyl, pyrrolidinyl,morpholino, tetrahydropyridinyl, tetrahydrofuranyl, dihydropyranyl, andtetrahydropyranyl, wherein the heterocycle is optionally substitutedwith a substituent selected from the group consisting of halo, OH, C₁-C₆alkyl, COR¹⁵, and COOR¹⁵; wherein R¹⁵ is C₁-C₆ alkyl; Y—Z is —CH₂O—,wherein the left hand side is joined with ring B; R⁵ is hydrogen, C₁-C₆alkyl, wherein the C₁-C₆ alkyl is optionally substituted with 1-5 halo;each R⁶ is independently selected from the group consisting of halo,C₁-C₆ alkyl, C₁-C₆ alkoxy, and C₁-C₆ alkylthio, wherein the C₁-C₆ alkylis optionally substituted with 1-5 halo; and p is 0, 1, 2, or
 3. 2. Thecompound of claim 1, or a tautomer thereof, or a pharmaceuticallyacceptable salt of each thereof, wherein p is
 0. 3. The compound ofclaim 1, or a tautomer thereof, or a pharmaceutically acceptable salt ofeach thereof, wherein ring A is pyrazolyl optionally substituted with aC₁-C₆ alkyl or C₁-C₆ alkoxy.
 4. The compound of claim 1, or a tautomerthereof, or a pharmaceutically acceptable salt of each thereof, whereinring A is pyrazolyl substituted with a C₁-C₆ alkyl.
 5. The compound ofclaim 1, or a tautomer thereof, or a pharmaceutically acceptable salt ofeach thereof, wherein ring B is a heterocycle selected from the groupconsisting of piperidinyl, pyrrolidinyl, morpholino,tetrahydropyridinyl, dihydropyranyl, and tetrahydropyranyl, wherein theheterocycle is optionally substituted with one substituent selected fromthe group consisting of methyl and —COCH₃.
 6. The compound of claim 1,or a tautomer thereof, or a pharmaceutically acceptable salt of eachthereof, wherein ring B is a heterocycle selected from the groupconsisting of piperidinyl, tetrahydropyridinyl, dihydropyranyl, andtetrahydropyranyl, wherein the heterocycle is optionally substitutedwith one substituent selected from the group consisting of methyl and—COCH₃.
 7. A pharmaceutical composition comprising a compound of claim1, or a tautomer thereof, or a pharmaceutically acceptable salt of eachthereof, and at least one pharmaceutically acceptable excipient.
 8. Amethod for increasing oxygen affinity of hemoglobin S in a subject inneed thereof, the method comprising administering to the subject acompound of claim 1, or a tautomer thereof, or a pharmaceuticallyacceptable salt of each thereof.
 9. A method for treating sickle celldisease comprising administering to a subject in need thereof a compoundof claim 1, or a tautomer thereof, or a pharmaceutically acceptable saltof each thereof.
 10. A compound selected from:

wherein

is a double or a single bond; R¹⁴ is C₁-C₆ alkyl, C₃-C₈ cycloalkyl,COR¹⁵, or COOR¹⁵; wherein R¹⁵ is C₁-C₆ alkyl; or an N oxide thereof, ora tautomer thereof, or a pharmaceutically acceptable salt of eachthereof.
 11. A compound of the formula

or a tautomer thereof, or a pharmaceutically acceptable salt of eachthereof.